X
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): OPT-302,Ranibizumab
Therapeutic Area: Ophthalmology Product Name: OPT-302
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $150.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering September 24, 2020
Details:
Opthea is working on a new drug that targets other VEGF proteins from those approved, including Bayer/Regeneron’s Eylea as well as Lucentis, namely VEGF-C and VEGF-D, for use in combination with VEGF-A drugs.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): OPT-302,Ranibizumab
Therapeutic Area: Ophthalmology Product Name: OPT-302
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 21, 2020
Details:
The outcome of the meetings supports the progression of OPT-302 into Phase 3 and pre-commercial development. The company is on-track to initiate Phase 3 trials in early 2021.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
